Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$53.30

-0.1401 (-0.26%)

14:07
04/21/17
04/21
14:07
04/21/17
14:07

Bristol-Myers receives 'positive' CHMP opinion on Opdivo approval

Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Opdivo is the first and only PD-1 immune checkpoint inhibitor for the treatment of patients with previously treated mUC to receive a positive CHMP opinion. Opdivo is already approved by the EC for six indications in four distinct tumor types. "We view the CHMP recommendation of Opdivo for previously treated locally advanced or metastatic urothelial carcinoma as an important milestone for the patients. Bristol-Myers Squibb looks forward to collaborating with the European Commission as it considers this potential new indication for Opdivo," said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

BMY Bristol-Myers
$53.30

-0.1401 (-0.26%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

GE

General Electric

$29.55

-0.72 (-2.38%)

07:26
04/24/17
04/24
07:26
04/24/17
07:26
Periodicals
GE CFO Bornstein concerned over U.S. business confidence, FT reports »

General Electric CFO Jeff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 22

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

07:25
04/24/17
04/24
07:25
04/24/17
07:25
Recommendations
C.R. Bard, Becton Dickinson analyst commentary  »

C.R. Bard price target…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

07:25
04/24/17
04/24
07:25
04/24/17
07:25
General news
FX Update: The euro surged »

FX Update: The euro…

MTSI

MACOM

$51.74

-0.07 (-0.14%)

, SBGI

Sinclair Broadcast

$39.90

-0.45 (-1.12%)

07:24
04/24/17
04/24
07:24
04/24/17
07:24
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$51.74

-0.07 (-0.14%)

SBGI

Sinclair Broadcast

$39.90

-0.45 (-1.12%)

NXST

Nexstar

$69.10

0.3 (0.44%)

TRCO

Tribune Media

$37.35

-0.77 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

BUD

AB InBev

$108.28

-0.81 (-0.74%)

07:24
04/24/17
04/24
07:24
04/24/17
07:24
Technical Analysis
AB InBev rallies in early pre-market trading »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

, AVXS

AveXis

$76.76

-0.24 (-0.31%)

07:23
04/24/17
04/24
07:23
04/24/17
07:23
Conference/Events
American Academy of Neurology »

69th Annual Meeting of…

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

AVXS

AveXis

$76.76

-0.24 (-0.31%)

CATB

Catabasis Pharmaceuticals

$1.45

-0.07 (-4.61%)

MNOV

MediciNova

$5.83

0.08 (1.39%)

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

FLKS

Flex Pharma

$3.08

-0.5 (-13.97%)

TGTX

TG Therapeutics

$10.30

-0.15 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 24

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 24

    Aug

VAC

Marriott Vacations

$104.42

1.54 (1.50%)

, WYN

Wyndham

$89.72

-0.03 (-0.03%)

07:22
04/24/17
04/24
07:22
04/24/17
07:22
Recommendations
Marriott Vacations, Wyndham, Extended Stay America analyst commentary  »

A few hotel chanins…

VAC

Marriott Vacations

$104.42

1.54 (1.50%)

WYN

Wyndham

$89.72

-0.03 (-0.03%)

STAY

Extended Stay America

$17.24

-0.07 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 04

    May

CGIX

Cancer Genetics

$4.05

0.1 (2.53%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Hot Stocks
Cancer Genetics launches Complete::IO panel »

Cancer Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$119.10

0.22 (0.19%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Upgrade
Travelers rating change  »

Travelers upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLT

FleetCor

$147.66

-2.07 (-1.38%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Recommendations
FleetCor analyst commentary  »

FleetCor should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

DB

Deutsche Bank

$16.50

-0.05 (-0.30%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Technical Analysis
Deutsche Bank rallies sharply in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

, FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

07:20
04/24/17
04/24
07:20
04/24/17
07:20
Conference/Events
RLJ Lodging Trust and Felcor Lodging to host joint conference call »

Joint Conference call to…

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 28

    Apr

AKTX

Akari Therapeutics

$20.50

4.13 (25.23%)

07:16
04/24/17
04/24
07:16
04/24/17
07:16
Hot Stocks
Akari: Interim Phase 2 PNH data demonstrate 'positive' response with Coversin »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

WGO

Winnebago

$26.25

0.15 (0.57%)

07:15
04/24/17
04/24
07:15
04/24/17
07:15
Initiation
Winnebago initiated  »

Winnebago initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$104.89

0.01 (0.01%)

07:14
04/24/17
04/24
07:14
04/24/17
07:14
Periodicals
Chevron to sell Bangladesh gas fields to Himalaya Energy, Reuters says »

Chevron has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

QTS

QTS Realty Trust

$52.90

-0.14 (-0.26%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Hot Stocks
Cara Therapeutics announces 'positive' data from Phase 1 trial of CR845 »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Steel Dynamics rating change  »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.72

-0.1 (-1.47%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
AK Steel rating change  »

AK Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

NUE

Nucor

$60.00

-0.35 (-0.58%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Nucor rating change  »

Nucor upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.42

-0.09 (-0.29%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
U.S. Steel rating change  »

U.S. Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
Breaking Hot Stocks news story on AkzoNobel, PPG »

AkzoNobel confirms third…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

SAGE Therapeutics

$72.82

1.19 (1.66%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
SAGE Therapeutics appoints Michael Cloonan as Chief Business Officer »

Sage Therapeutics (SAGE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOMA

XOMA

$7.73

0.26 (3.48%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
XOMA says X213 shown to be safe and effective in phase 2 study »

XOMA Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

AMDA

Amedica

$0.38

0.01 (2.70%)

07:08
04/24/17
04/24
07:08
04/24/17
07:08
Hot Stocks
Amedica announces regulatory clearance to market, sell Valeo in Australia »

Amedica Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.